The Experts below are selected from a list of 276 Experts worldwide ranked by ideXlab platform
Frank Verhaegen - One of the best experts on this subject based on the ideXlab platform.
-
WE‐A‐BRA‐03: Towards Real‐Time Ultrasound Image‐Guided Abdominal Radiotherapy
Medical Physics, 2012Co-Authors: S Van Der Meer, John Wong, E Bloemen, Davide Fontanarosa, M Lachaine, Frank VerhaegenAbstract:Purpose: Accurate tumor positioning in stereotactic body Radiotherapy of Abdominal lesions is often hampered by organ motion and set‐up errors. The problems of the daily variation (interfractional motion) in tumor position can be partially corrected with on‐line soft‐tissue image‐guidedRadiotherapy. However, a greater challenge is to also capture the movement during treatment (intrafractional motion). Methods: To study the feasibility of Abdominal real‐time volumetric soft‐tissue image‐guidance with ultrasound(US)imaging, we are investigating several aspects each with their own challenges: 3DUS volumetric imaging, 2DUS time series of the organ motion, roboticUS probe placement, US auto‐contouring and contrast enhanced US (CEUS). Results: Currently, 3DUS imaging is used first to correct for the set‐up errors as well as interfractional organ motion. One of the conditions for reliable and accurate results in this part is acquiring USimages without artifacts due to breathing motion. For interfractional corrections, this can be realized by imaging during breath hold. In order to track intrafractional tumor and organ motion, including breathing induced, we are moving towards acquisition of temporal 3D image series. As an interim step, we discuss acquisition of temporal 2D datasets. As opposed to prostate, where the US probe can be placed on the perineum during treatment to avoid interaction with the radiation beam, the probe positions required for liver are more complex. Therefore, we are developing robot‐ assisted positioning of the probe. Not all Abdominal lesions are clearly visible on USimages. By introducing CEUS, more tumors will have increased contrast allowing tracking them. With real‐time tumor tracking it is impossible to manually delineate structures. Therefore auto‐contouring algorithms for this specific application are under investigation. Conclusion: By combining all the investigated technologies we aim to develop a reliable real‐time volumetric soft‐tissue USimage‐guidance system for clinical implementation. Research sponsored by ElektaLearning Objectives:1‐ understand the challenges of in‐vivo real time motion monitoring2‐ understand the role of ultrasound imaging in in‐vivo real time motion monitoring3‐learn about our efforts to develop a system for ultrasound‐ based in‐vivo real time motion monitoring
-
we a bra 03 towards real time ultrasound image guided Abdominal Radiotherapy
Medical Physics, 2012Co-Authors: S Van Der Meer, John Wong, E Bloemen, Davide Fontanarosa, M Lachaine, Frank VerhaegenAbstract:Purpose: Accurate tumor positioning in stereotactic body Radiotherapy of Abdominal lesions is often hampered by organ motion and set‐up errors. The problems of the daily variation (interfractional motion) in tumor position can be partially corrected with on‐line soft‐tissue image‐guidedRadiotherapy. However, a greater challenge is to also capture the movement during treatment (intrafractional motion). Methods: To study the feasibility of Abdominal real‐time volumetric soft‐tissue image‐guidance with ultrasound(US)imaging, we are investigating several aspects each with their own challenges: 3DUS volumetric imaging, 2DUS time series of the organ motion, roboticUS probe placement, US auto‐contouring and contrast enhanced US (CEUS). Results: Currently, 3DUS imaging is used first to correct for the set‐up errors as well as interfractional organ motion. One of the conditions for reliable and accurate results in this part is acquiring USimages without artifacts due to breathing motion. For interfractional corrections, this can be realized by imaging during breath hold. In order to track intrafractional tumor and organ motion, including breathing induced, we are moving towards acquisition of temporal 3D image series. As an interim step, we discuss acquisition of temporal 2D datasets. As opposed to prostate, where the US probe can be placed on the perineum during treatment to avoid interaction with the radiation beam, the probe positions required for liver are more complex. Therefore, we are developing robot‐ assisted positioning of the probe. Not all Abdominal lesions are clearly visible on USimages. By introducing CEUS, more tumors will have increased contrast allowing tracking them. With real‐time tumor tracking it is impossible to manually delineate structures. Therefore auto‐contouring algorithms for this specific application are under investigation. Conclusion: By combining all the investigated technologies we aim to develop a reliable real‐time volumetric soft‐tissue USimage‐guidance system for clinical implementation. Research sponsored by ElektaLearning Objectives:1‐ understand the challenges of in‐vivo real time motion monitoring2‐ understand the role of ultrasound imaging in in‐vivo real time motion monitoring3‐learn about our efforts to develop a system for ultrasound‐ based in‐vivo real time motion monitoring
-
we a bra 03 towards real time ultrasound image guided Abdominal Radiotherapy
Faculty of Health, 2012Co-Authors: S Van Der Meer, John Wong, E Bloemen, Davide Fontanarosa, M Lachaine, Frank VerhaegenAbstract:Accurate tumor positioning in stereotactic body Radiotherapy of Abdominal lesions is often hampered by organ motion and set-up errors. The problems of the daily variation (interfractional motion) in tumor position can be partially corrected with on-line soft-tissue image-guided Radiotherapy. However, a greater challenge is to also capture the movement during treatment (intrafractional motion).
J Debus - One of the best experts on this subject based on the ideXlab platform.
-
intensity modulated whole Abdominal Radiotherapy after surgery and carboplatin taxane chemotherapy for advanced ovarian cancer phase i study
International Journal of Radiation Oncology Biology Physics, 2010Co-Authors: N Rochet, Florian Sterzing, Alexandra D Jensen, J Dinkel, Klaus Herfarth, Kai Schubert, Michael H R Eichbaum, Andreas Schneeweiss, Christof Sohn, J DebusAbstract:Purpose To assess the feasibility and toxicity of consolidative intensity-modulated whole Abdominal Radiotherapy (WAR) after surgery and chemotherapy in high-risk patients with advanced ovarian cancer. Methods and Materials Ten patients with optimally debulked ovarian cancer International Federation of Gynecology and Obstetrics Stage IIIc were treated in a Phase I study with intensity-modulated WAR up to a total dose of 30 Gy in 1.5-Gy fractions as consolidation therapy after adjuvant carboplatin/taxane chemotherapy. Treatment was delivered using intensity-modulated Radiotherapy in a step-and-shoot technique ( n = 3) or a helical tomotherapy technique ( n = 7). The planning target volume included the entire peritoneal cavity and the pelvic and para-aortal node regions. Organs at risk were kidneys, liver, heart, vertebral bodies, and pelvic bones. Results Intensity-modulated WAR resulted in an excellent coverage of the planning target volume and an effective sparing of the organs at risk. The treatment was well tolerated, and no severe Grade 4 acute side effects occurred. Common Toxicity Criteria Grade III toxicities were as follows: diarrhea ( n = 1), thrombocytopenia ( n = 1), and leukopenia ( n = 3). Radiotherapy could be completed by all the patients without any toxicity-related interruption. Median follow-up was 23 months, and 4 patients had tumor recurrence (intraperitoneal progression, n = 3; hepatic metastasis, n = 1). Small bowel obstruction caused by adhesions occurred in 3 patients. Conclusions The results of this Phase I study showed for the first time, to our knowledge, the clinical feasibility of intensity-modulated whole Abdominal Radiotherapy, which could offer a new therapeutic option for consolidation treatment of advanced ovarian carcinoma after adjuvant chemotherapy in selected subgroups of patients. We initiated a Phase II study to further evaluate the toxicity of this intensive multimodal treatment.
-
Intensity-Modulated Whole Abdominal Radiotherapy After Surgery and Carboplatin/Taxane Chemotherapy for Advanced Ovarian Cancer: Phase I Study
International Journal of Radiation Oncology Biology Physics, 2009Co-Authors: N Rochet, Florian Sterzing, Alexandra D Jensen, J Dinkel, Klaus Herfarth, Kai Schubert, Michael H R Eichbaum, Andreas Schneeweiss, Christof Sohn, J DebusAbstract:Purpose To assess the feasibility and toxicity of consolidative intensity-modulated whole Abdominal Radiotherapy (WAR) after surgery and chemotherapy in high-risk patients with advanced ovarian cancer. Methods and Materials Ten patients with optimally debulked ovarian cancer International Federation of Gynecology and Obstetrics Stage IIIc were treated in a Phase I study with intensity-modulated WAR up to a total dose of 30 Gy in 1.5-Gy fractions as consolidation therapy after adjuvant carboplatin/taxane chemotherapy. Treatment was delivered using intensity-modulated Radiotherapy in a step-and-shoot technique ( n = 3) or a helical tomotherapy technique ( n = 7). The planning target volume included the entire peritoneal cavity and the pelvic and para-aortal node regions. Organs at risk were kidneys, liver, heart, vertebral bodies, and pelvic bones. Results Intensity-modulated WAR resulted in an excellent coverage of the planning target volume and an effective sparing of the organs at risk. The treatment was well tolerated, and no severe Grade 4 acute side effects occurred. Common Toxicity Criteria Grade III toxicities were as follows: diarrhea ( n = 1), thrombocytopenia ( n = 1), and leukopenia ( n = 3). Radiotherapy could be completed by all the patients without any toxicity-related interruption. Median follow-up was 23 months, and 4 patients had tumor recurrence (intraperitoneal progression, n = 3; hepatic metastasis, n = 1). Small bowel obstruction caused by adhesions occurred in 3 patients. Conclusions The results of this Phase I study showed for the first time, to our knowledge, the clinical feasibility of intensity-modulated whole Abdominal Radiotherapy, which could offer a new therapeutic option for consolidation treatment of advanced ovarian carcinoma after adjuvant chemotherapy in selected subgroups of patients. We initiated a Phase II study to further evaluate the toxicity of this intensive multimodal treatment.
S Van Der Meer - One of the best experts on this subject based on the ideXlab platform.
-
WE‐A‐BRA‐03: Towards Real‐Time Ultrasound Image‐Guided Abdominal Radiotherapy
Medical Physics, 2012Co-Authors: S Van Der Meer, John Wong, E Bloemen, Davide Fontanarosa, M Lachaine, Frank VerhaegenAbstract:Purpose: Accurate tumor positioning in stereotactic body Radiotherapy of Abdominal lesions is often hampered by organ motion and set‐up errors. The problems of the daily variation (interfractional motion) in tumor position can be partially corrected with on‐line soft‐tissue image‐guidedRadiotherapy. However, a greater challenge is to also capture the movement during treatment (intrafractional motion). Methods: To study the feasibility of Abdominal real‐time volumetric soft‐tissue image‐guidance with ultrasound(US)imaging, we are investigating several aspects each with their own challenges: 3DUS volumetric imaging, 2DUS time series of the organ motion, roboticUS probe placement, US auto‐contouring and contrast enhanced US (CEUS). Results: Currently, 3DUS imaging is used first to correct for the set‐up errors as well as interfractional organ motion. One of the conditions for reliable and accurate results in this part is acquiring USimages without artifacts due to breathing motion. For interfractional corrections, this can be realized by imaging during breath hold. In order to track intrafractional tumor and organ motion, including breathing induced, we are moving towards acquisition of temporal 3D image series. As an interim step, we discuss acquisition of temporal 2D datasets. As opposed to prostate, where the US probe can be placed on the perineum during treatment to avoid interaction with the radiation beam, the probe positions required for liver are more complex. Therefore, we are developing robot‐ assisted positioning of the probe. Not all Abdominal lesions are clearly visible on USimages. By introducing CEUS, more tumors will have increased contrast allowing tracking them. With real‐time tumor tracking it is impossible to manually delineate structures. Therefore auto‐contouring algorithms for this specific application are under investigation. Conclusion: By combining all the investigated technologies we aim to develop a reliable real‐time volumetric soft‐tissue USimage‐guidance system for clinical implementation. Research sponsored by ElektaLearning Objectives:1‐ understand the challenges of in‐vivo real time motion monitoring2‐ understand the role of ultrasound imaging in in‐vivo real time motion monitoring3‐learn about our efforts to develop a system for ultrasound‐ based in‐vivo real time motion monitoring
-
we a bra 03 towards real time ultrasound image guided Abdominal Radiotherapy
Medical Physics, 2012Co-Authors: S Van Der Meer, John Wong, E Bloemen, Davide Fontanarosa, M Lachaine, Frank VerhaegenAbstract:Purpose: Accurate tumor positioning in stereotactic body Radiotherapy of Abdominal lesions is often hampered by organ motion and set‐up errors. The problems of the daily variation (interfractional motion) in tumor position can be partially corrected with on‐line soft‐tissue image‐guidedRadiotherapy. However, a greater challenge is to also capture the movement during treatment (intrafractional motion). Methods: To study the feasibility of Abdominal real‐time volumetric soft‐tissue image‐guidance with ultrasound(US)imaging, we are investigating several aspects each with their own challenges: 3DUS volumetric imaging, 2DUS time series of the organ motion, roboticUS probe placement, US auto‐contouring and contrast enhanced US (CEUS). Results: Currently, 3DUS imaging is used first to correct for the set‐up errors as well as interfractional organ motion. One of the conditions for reliable and accurate results in this part is acquiring USimages without artifacts due to breathing motion. For interfractional corrections, this can be realized by imaging during breath hold. In order to track intrafractional tumor and organ motion, including breathing induced, we are moving towards acquisition of temporal 3D image series. As an interim step, we discuss acquisition of temporal 2D datasets. As opposed to prostate, where the US probe can be placed on the perineum during treatment to avoid interaction with the radiation beam, the probe positions required for liver are more complex. Therefore, we are developing robot‐ assisted positioning of the probe. Not all Abdominal lesions are clearly visible on USimages. By introducing CEUS, more tumors will have increased contrast allowing tracking them. With real‐time tumor tracking it is impossible to manually delineate structures. Therefore auto‐contouring algorithms for this specific application are under investigation. Conclusion: By combining all the investigated technologies we aim to develop a reliable real‐time volumetric soft‐tissue USimage‐guidance system for clinical implementation. Research sponsored by ElektaLearning Objectives:1‐ understand the challenges of in‐vivo real time motion monitoring2‐ understand the role of ultrasound imaging in in‐vivo real time motion monitoring3‐learn about our efforts to develop a system for ultrasound‐ based in‐vivo real time motion monitoring
-
we a bra 03 towards real time ultrasound image guided Abdominal Radiotherapy
Faculty of Health, 2012Co-Authors: S Van Der Meer, John Wong, E Bloemen, Davide Fontanarosa, M Lachaine, Frank VerhaegenAbstract:Accurate tumor positioning in stereotactic body Radiotherapy of Abdominal lesions is often hampered by organ motion and set-up errors. The problems of the daily variation (interfractional motion) in tumor position can be partially corrected with on-line soft-tissue image-guided Radiotherapy. However, a greater challenge is to also capture the movement during treatment (intrafractional motion).
Phb Willemse - One of the best experts on this subject based on the ideXlab platform.
-
long term morbidity of adjuvant whole Abdominal Radiotherapy wart or chemotherapy for early stage ovarian cancer
European Journal of Cancer, 2009Co-Authors: Mirjam J A Engelen, B J Snel, M Schaapveld, Elisabeth Pras, E G E De Vries, Jourik A Gietema, Phb WillemseAbstract:Abstract The aim of the study was to evaluate long-term toxicity of adjuvant treatment in early stage ovarian cancer survivors. Data from all patients treated in one hospital for early stage ovarian cancer diagnosed between 1980 and 1990 were collected using a structured data form. In 93 FIGO stages I and II patients, cytoreductive and staging surgery was performed; 15 received no adjuvant treatment (controls), 39 whole Abdominal Radiotherapy (WART) and 39 platin-based chemotherapy. Median age at diagnosis was 54 years (range 21–83 years). During follow-up, 49/93 (53%) patients have died with a median overall survival of 18.4 years (95% CI 12.8–23.9). In both the Radiotherapy and the chemotherapy group, 50% of patients reported long-term side-effects (all grades) versus 13% of controls. Two patients in the WART group died from bowel complications. Secondary malignancies were observed in 16 patients. Of all patients alive at the last follow-up, 12/17 (71%) patients treated with Radiotherapy and 11/18 (61%) treated with chemotherapy experienced long-term morbidity versus 2/9 (22%) controls (P = 0.03). In conclusion: Long-term follow-up of early stage ovarian cancer patients showed lasting GI morbidity in the survivors treated with adjuvant Radiotherapy, which has therefore become obsolete. Cisplatin-based chemotherapy caused peripheral neuropathy versus virtual absence of problems in the survivors of just surgery, emphasising the need for strict criteria before instigating adjuvant treatment.
N Rochet - One of the best experts on this subject based on the ideXlab platform.
-
intensity modulated whole Abdominal Radiotherapy after surgery and carboplatin taxane chemotherapy for advanced ovarian cancer phase i study
International Journal of Radiation Oncology Biology Physics, 2010Co-Authors: N Rochet, Florian Sterzing, Alexandra D Jensen, J Dinkel, Klaus Herfarth, Kai Schubert, Michael H R Eichbaum, Andreas Schneeweiss, Christof Sohn, J DebusAbstract:Purpose To assess the feasibility and toxicity of consolidative intensity-modulated whole Abdominal Radiotherapy (WAR) after surgery and chemotherapy in high-risk patients with advanced ovarian cancer. Methods and Materials Ten patients with optimally debulked ovarian cancer International Federation of Gynecology and Obstetrics Stage IIIc were treated in a Phase I study with intensity-modulated WAR up to a total dose of 30 Gy in 1.5-Gy fractions as consolidation therapy after adjuvant carboplatin/taxane chemotherapy. Treatment was delivered using intensity-modulated Radiotherapy in a step-and-shoot technique ( n = 3) or a helical tomotherapy technique ( n = 7). The planning target volume included the entire peritoneal cavity and the pelvic and para-aortal node regions. Organs at risk were kidneys, liver, heart, vertebral bodies, and pelvic bones. Results Intensity-modulated WAR resulted in an excellent coverage of the planning target volume and an effective sparing of the organs at risk. The treatment was well tolerated, and no severe Grade 4 acute side effects occurred. Common Toxicity Criteria Grade III toxicities were as follows: diarrhea ( n = 1), thrombocytopenia ( n = 1), and leukopenia ( n = 3). Radiotherapy could be completed by all the patients without any toxicity-related interruption. Median follow-up was 23 months, and 4 patients had tumor recurrence (intraperitoneal progression, n = 3; hepatic metastasis, n = 1). Small bowel obstruction caused by adhesions occurred in 3 patients. Conclusions The results of this Phase I study showed for the first time, to our knowledge, the clinical feasibility of intensity-modulated whole Abdominal Radiotherapy, which could offer a new therapeutic option for consolidation treatment of advanced ovarian carcinoma after adjuvant chemotherapy in selected subgroups of patients. We initiated a Phase II study to further evaluate the toxicity of this intensive multimodal treatment.
-
Intensity-Modulated Whole Abdominal Radiotherapy After Surgery and Carboplatin/Taxane Chemotherapy for Advanced Ovarian Cancer: Phase I Study
International Journal of Radiation Oncology Biology Physics, 2009Co-Authors: N Rochet, Florian Sterzing, Alexandra D Jensen, J Dinkel, Klaus Herfarth, Kai Schubert, Michael H R Eichbaum, Andreas Schneeweiss, Christof Sohn, J DebusAbstract:Purpose To assess the feasibility and toxicity of consolidative intensity-modulated whole Abdominal Radiotherapy (WAR) after surgery and chemotherapy in high-risk patients with advanced ovarian cancer. Methods and Materials Ten patients with optimally debulked ovarian cancer International Federation of Gynecology and Obstetrics Stage IIIc were treated in a Phase I study with intensity-modulated WAR up to a total dose of 30 Gy in 1.5-Gy fractions as consolidation therapy after adjuvant carboplatin/taxane chemotherapy. Treatment was delivered using intensity-modulated Radiotherapy in a step-and-shoot technique ( n = 3) or a helical tomotherapy technique ( n = 7). The planning target volume included the entire peritoneal cavity and the pelvic and para-aortal node regions. Organs at risk were kidneys, liver, heart, vertebral bodies, and pelvic bones. Results Intensity-modulated WAR resulted in an excellent coverage of the planning target volume and an effective sparing of the organs at risk. The treatment was well tolerated, and no severe Grade 4 acute side effects occurred. Common Toxicity Criteria Grade III toxicities were as follows: diarrhea ( n = 1), thrombocytopenia ( n = 1), and leukopenia ( n = 3). Radiotherapy could be completed by all the patients without any toxicity-related interruption. Median follow-up was 23 months, and 4 patients had tumor recurrence (intraperitoneal progression, n = 3; hepatic metastasis, n = 1). Small bowel obstruction caused by adhesions occurred in 3 patients. Conclusions The results of this Phase I study showed for the first time, to our knowledge, the clinical feasibility of intensity-modulated whole Abdominal Radiotherapy, which could offer a new therapeutic option for consolidation treatment of advanced ovarian carcinoma after adjuvant chemotherapy in selected subgroups of patients. We initiated a Phase II study to further evaluate the toxicity of this intensive multimodal treatment.
